Polymer Nanoparticles for the Delivery of Anticancer Drugs

Dear Colleagues,

Nanotechnology is at the commanding height of strategic technology in the 21st century, among which nanoparticles are revolutionizing the field of drug delivery, especially regarding cancer, their therapeutic effects in practical applications though still being far from satisfactory on account of their poor water solubility and poor pharmacokinetics. Luckily, the booming nanocarriers have introduced bright prospects for gaining encouraging therapeutic outcomes, since they can be engineered to enhance the solubility and circulation time of drugs, as well as efficiently bringing drugs to cancer cells. Accordingly, a series of promising polymer nanoparticles are being developed for the delivery of anticancer drugs, such as PEG-PLA polymer micelles, PLGA nanoparticles, liposome, gold nanoparticles, etc. Additionally, advanced delivery systems have also been designed to deliver drugs specifically to the tumor site, based on their stimuli-responsive properties and cancer cell-specific markers. Nevertheless, the further exploration of identifying targeted molecules and designing nanocarriers is still worth continuing. Therefore, we would like to invite you to contribute both reviews and original articles highlighting recent progress in the development of polymer nanoparticles for the delivery of anticancer drugs, which will be published as part of a Special Issue entitled “Polymer Nanoparticles for the Delivery of Anticancer Drugs”. Main topics include, but are not limited to: polymer nanoparticles for chemotherapeutic drug delivery, nucleic acid delivery, chemotherapeutic drug and nucleic acid-based co-delivery, photosensitizer delivery, etc.

We look forward to receiving your contributions.

Dr. Wei Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.